{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:32:00Z","timestamp":1791145920624,"version":"4.1.0"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/1008-682x.129133","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T07:53:01Z","timestamp":1398844381000},"page":"387","source":"Crossref","is-referenced-by-count":48,"title":["Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer"],"prefix":"10.4103","volume":"16","author":[{"given":"MarkN","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bershadskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Sokoloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EricA","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.129133-1","first-page":"2893","volume-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"key-10.4103\/1008-682X.129133-2","first-page":"1079","volume-title":"International variation in prostate cancer incidence and mortality rates","author":"Center","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.129133-3","first-page":"9","volume-title":"Cancer statistics, 2014","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/1008-682X.129133-4","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7."},{"key":"key-10.4103\/1008-682X.129133-5","first-page":"S15","volume-title":"Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events","author":"Singer","year":"2012","journal-title":"Urol Oncol"},{"key":"key-10.4103\/1008-682X.129133-6","first-page":"76","volume-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"key-10.4103\/1008-682X.129133-7","first-page":"429","volume-title":"Castration-resistant prostate cancer: AUA Guideline","author":"Cookson","year":"2013","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.129133-8","first-page":"16","volume-title":"Androgen receptors.Steroid- and tissue-specific retention of a 17 beta-hydroxy-5 alpha-androstan-3-one-protein complex by the cell nuclei of ventral prostate","author":"Fang","year":"1971","journal-title":"J Biol Chem"},{"key":"key-10.4103\/1008-682X.129133-9","first-page":"644","volume-title":"Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer","author":"Nelson","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-10","first-page":"417","volume-title":"Role of stromal-epithelial interactions in hormonal responses","author":"Cunha","year":"2004","journal-title":"Arch Histol Cytol"},{"key":"key-10.4103\/1008-682X.129133-11","first-page":"244","volume-title":"Molecular pathogenesis and progression of prostate cancer","author":"Schrecengost","year":"2013","journal-title":"Semin Oncol"},{"key":"key-10.4103\/1008-682X.129133-12","first-page":"644","volume-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"key-10.4103\/1008-682X.129133-13","first-page":"1069","volume-title":"Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer","author":"Lin","year":"2009","journal-title":"Cell"},{"key":"key-10.4103\/1008-682X.129133-14","doi-asserted-by":"crossref","unstructured":"Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, et al. Identification of novel TMPRSS2: ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 2013 May 27. doi: 10.1038\/onc.2013.176. [Epub ahead of print].","DOI":"10.1038\/onc.2013.176"},{"key":"key-10.4103\/1008-682X.129133-15","first-page":"966","volume-title":"A step toward functionally characterized prostate cancer molecular subtypes","author":"Demichelis","year":"2013","journal-title":"Nat Med"},{"key":"key-10.4103\/1008-682X.129133-16","first-page":"1023","volume-title":"ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss","author":"Chen","year":"2013","journal-title":"Nat Med"},{"key":"key-10.4103\/1008-682X.129133-17","first-page":"1165","volume-title":"Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone","author":"Grino","year":"1990","journal-title":"Endocrinology"},{"key":"key-10.4103\/1008-682X.129133-18","first-page":"25801","volume-title":"Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone","author":"Askew","year":"2007","journal-title":"J Biol Chem"},{"key":"key-10.4103\/1008-682X.129133-19","first-page":"1213","volume-title":"Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism","author":"Imperato-McGinley","year":"1974","journal-title":"Science"},{"key":"key-10.4103\/1008-682X.129133-20","first-page":"5033","volume-title":"Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer","author":"Mostaghel","year":"2007","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-21","first-page":"52","volume-title":"Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer","author":"Labrie","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key-10.4103\/1008-682X.129133-22","first-page":"440","volume-title":"DHT concentrations in human prostate cancer tissue","author":"Geller","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.129133-23","first-page":"4653","volume-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","author":"Titus","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-24","first-page":"4447","volume-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-25","first-page":"708","volume-title":"Minireview: androgen metabolism in castration-resistant prostate cancer","author":"Sharifi","year":"2013","journal-title":"Mol Endocrinol"},{"key":"key-10.4103\/1008-682X.129133-26","first-page":"938","volume-title":"\"Getting from here to there\" - Mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer","author":"Sharifi","year":"2010","journal-title":"J Investig Med"},{"key":"key-10.4103\/1008-682X.129133-27","first-page":"2815","volume-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-28","first-page":"6503","volume-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-29","first-page":"6407","volume-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-30","first-page":"6142","volume-title":"Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors","author":"Mitsiades","year":"2012","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-31","first-page":"1241","volume-title":"Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer","author":"Attard","year":"2005","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.129133-32","first-page":"1204","volume-title":"Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal","author":"Small","year":"1997","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.129133-33","first-page":"1025","volume-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-34","first-page":"2463","volume-title":"Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer","author":"Potter","year":"1995","journal-title":"J Med Chem"},{"key":"key-10.4103\/1008-682X.129133-35","first-page":"3319","volume-title":"3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450 (17 alpha) (17 alpha-hydroxylase\/C17,20-lyase).Potential nonsteroidal agents for the treatment of prostatic cancer","author":"Chan","year":"1996","journal-title":"J Med Chem"},{"key":"key-10.4103\/1008-682X.129133-36","first-page":"2317","volume-title":"Hormonal impact of the 17alpha-hydroxylase\/C (17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","author":"O\u2032Donnell","year":"2004","journal-title":"Br J Cancer"},{"key":"key-10.4103\/1008-682X.129133-37","first-page":"4563","volume-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-38","first-page":"1481","volume-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-39","first-page":"3742","volume-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-40","first-page":"4854","volume-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-41","first-page":"1489","volume-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-42","first-page":"1496","volume-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-43","first-page":"1995","volume-title":"Abiraterone and increased survival in metastatic prostate cancer","author":"de","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-44","first-page":"983","volume-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.129133-45","unstructured":"Ning YM, Kluetz P, Liu K. Center for drug evaluation and research: clinical review of NDA 202379. Zytiga\u2122 (abiraterone acetate) for metastatic castration-resistant prostate cancer after prior chemotherapy; 2011."},{"key":"key-10.4103\/1008-682X.129133-46","first-page":"R175","volume-title":"Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy","author":"Cai","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"key-10.4103\/1008-682X.129133-47","first-page":"138","volume-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-48","first-page":"5009","volume-title":"Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)","author":"Rathkopf","year":"2013","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-49","doi-asserted-by":"crossref","unstructured":"Kluetz PG, Ning YM, Maher VE, Zhang L, Tang S, et al. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2013; 19: 6650-6.","DOI":"10.1158\/1078-0432.CCR-13-2134"},{"key":"key-10.4103\/1008-682X.129133-50","first-page":"6302","volume-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","author":"de","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-51","first-page":"3903","volume-title":"Circulating tumor cells as biomarkers in prostate cancer","author":"Danila","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-52","first-page":"2912","volume-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-53","first-page":"897","volume-title":"TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate","author":"Danila","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.129133-54","first-page":"2791","volume-title":"Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial","author":"Ryan","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-55","unstructured":"Scher H, Heller G, Molina A, Attard G, McCormack R, et al. Evaluation of a composite biomarker panel including circulating tumor cell enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer: presented at: European Cancer Congress 2013; Amsterdam."},{"key":"key-10.4103\/1008-682X.129133-56","unstructured":"Janssen Diagnostics LPR. New study shows circulating tumor cell enumeration-as part of composite biomarker panel-may serve as a surrogate for efficacy response in metastatic castration-resistant prostate cancer; 2013."},{"key":"key-10.4103\/1008-682X.129133-57","first-page":"507","volume-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.129133-58","doi-asserted-by":"crossref","unstructured":"Procopio G, Grassi P, Testa I, Verzoni E, Torri V, et al. Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 2013 Sep 21. [Epub ahead of print].","DOI":"10.1097\/COC.0b013e3182a790ce"},{"key":"key-10.4103\/1008-682X.129133-59","first-page":"325","volume-title":"Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer","author":"Pezaro","year":"2013","journal-title":"Br J Cancer"},{"key":"key-10.4103\/1008-682X.129133-60","first-page":"1210","volume-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.129133-61","first-page":"1193","volume-title":"Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial","author":"Basch","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.129133-62","first-page":"4319","volume-title":"Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer","author":"Yamaoka","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-63","first-page":"6383","volume-title":"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer","author":"Kaku","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"key-10.4103\/1008-682X.129133-64","first-page":"115","volume-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","author":"Yamaoka","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key-10.4103\/1008-682X.129133-65","first-page":"98","volume-title":"Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I\/II study","author":"Agus","year":"2012","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-66","first-page":"59","volume-title":"A phase I\/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): updated phase II results","author":"Petrylak","year":"2013","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-67","first-page":"7","volume-title":"Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (Tak-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (Elm-Pc 5 trial).ASCO Meeting Abstracts, 2014","author":"Dreicer","year":"32(4","journal-title":""},{"key":"key-10.4103\/1008-682X.129133-68","first-page":"4549","volume-title":"Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): updated results of a phase II study","author":"George","year":"2012","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-69","first-page":"e15167","volume-title":"VT-464: a novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC)","author":"Eisner","year":"2012","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-70","unstructured":"Abbott DH, Eisner JR, Bird IM, Rafferty SW, Moore WR, et al. Plasma steroid concentrations in male Rhesus monkeys following treatment with the P450c17 (CYP17) inhibitors VT-464 and abiraterone acetate: a comparison to human 17,20-Lyase (lyase) and combined Lyase\/17\u03b1-hydroxylase (hydroxylase) deficiencies. Endocr Rev 2012; 33: SAT-256. (03_MeetingAbstracts)."},{"key":"key-10.4103\/1008-682X.129133-71","unstructured":"Eisner JR, Abbott DH, Bird IM, Rafferty SW, Moore WR, et al. Assessment of steroid hormones upstream of p450c17 (CYP17) in chemically castrate male rhesus monkeys following treatment with the CYP17 inhibitors VT-464 and abiraterone acetate (AA). Endocr Rev 2012; 33: SAT-266. (03_MeetingAbstracts)."},{"key":"key-10.4103\/1008-682X.129133-72","first-page":"4671","volume-title":"Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft","author":"Figg","year":"2012","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-73","first-page":"2972","volume-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","author":"Handratta","year":"2005","journal-title":"J Med Chem"},{"key":"key-10.4103\/1008-682X.129133-74","first-page":"2348","volume-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer","author":"Vasaitis","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key-10.4103\/1008-682X.129133-75","first-page":"184","volume-title":"Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis","author":"Jacoby","year":"2013","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-76","first-page":"3777","volume-title":"Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells","author":"Soifer","year":"2012","journal-title":"J Biol Chem"},{"key":"key-10.4103\/1008-682X.129133-77","first-page":"4665","volume-title":"Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC)","author":"Montgomery","year":"2012","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-78","first-page":"1268","volume-title":"Synthesis and biological evaluations of putative metabolically stable analogs of VN\/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN\/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model","author":"Bruno","year":"2011","journal-title":"Steroids"},{"key":"key-10.4103\/1008-682X.129133-79","doi-asserted-by":"crossref","unstructured":"Taplin ME, Chu F, Morrison J, Pili R, Rettig M, et al. ARMOR1: safety of galeterone (TOK-001) in a phase 1 clinical trial in chemotherapy na\u00efve patients with castration resistant prostate cancer (CRPC). In: proceedings of the 103 rd Annual Meeting of the American Association for Cancer Research; 2012; Chicago, IL. Philadelphia (PA): AACR. Cancer Res 2012; 72: nr CT-07.","DOI":"10.1158\/1538-7445.AM2012-CT-07"},{"key":"key-10.4103\/1008-682X.129133-80","first-page":"e16075","volume-title":"Comparison of the pharmacokinetics (PK) of galeterone novel oral formulations","author":"Kramer","year":"2013","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-81","doi-asserted-by":"crossref","unstructured":"Yuan X, Cai C, Chen S, Chen S, Yu Z, et al. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2013 Jun 10. doi: 10.1038\/onc.2013.235. [Epub ahead of print].","DOI":"10.1038\/onc.2013.235"},{"key":"key-10.4103\/1008-682X.129133-82","first-page":"5913","volume-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-83","first-page":"3571","volume-title":"Abiraterone inhibits 3b-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer","author":"Li","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-84","first-page":"619","volume-title":"Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes","author":"Wright","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key-10.4103\/1008-682X.129133-85","first-page":"2565","volume-title":"SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer","author":"Yang","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-86","first-page":"426","volume-title":"Castration-resistant prostate cancer: adaptive responses in the androgen axis","author":"Egan","year":"2014","journal-title":"Oncogene"},{"key":"key-10.4103\/1008-682X.129133-87","first-page":"1074","volume-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"key-10.4103\/1008-682X.129133-88","first-page":"3353","volume-title":"Molecular pathways: inhibiting steroid biosynthesis in prostate cancer","author":"Ferraldeschi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-89","first-page":"13728","volume-title":"Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer","author":"Chang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/1008-682X.129133-90","first-page":"888","volume-title":"Fast and flawed or scientifically sound: the argument for administering oral oncology drugs during fasting","author":"Todd","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-91","first-page":"2176","volume-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","author":"Richards","year":"2012","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-92","first-page":"665","volume-title":"The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens","author":"Veldscholte","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key-10.4103\/1008-682X.129133-93","first-page":"1393","volume-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-94","first-page":"69","volume-title":"The androgen receptor in hormone-refractory prostate cancer","author":"Mao","year":"2009","journal-title":"Asian J Androl"},{"key":"key-10.4103\/1008-682X.129133-95","first-page":"862","volume-title":"Invasive prostate carcinoma driven by c-Src and androgen receptor synergy","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-96","first-page":"849","volume-title":"Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer","author":"Logothetis","year":"2013","journal-title":"Cancer Discov"},{"key":"key-10.4103\/1008-682X.129133-97","first-page":"1134","volume-title":"Dual roles of PARP-1 promote cancer growth and progression","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"key-10.4103\/1008-682X.129133-98","first-page":"664","volume-title":"Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"key":"key-10.4103\/1008-682X.129133-99","first-page":"575","volume-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"key-10.4103\/1008-682X.129133-100","first-page":"572","volume-title":"Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer","author":"Hodgson","year":"2011","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-101","first-page":"1187","volume-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-102","doi-asserted-by":"crossref","unstructured":"Efstathiou E, Titus MA, Tsavachidou D, Wen S, Hoang A, et al. Modulation of intracrine androgen signaling in bone metastatic castrate resistant prostate cancer (bmCRPC) by MDV3100. In: proceedings of the 103 rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia, (PA): AACR. Cancer Res 2012; 72: nr 2696.","DOI":"10.1158\/1538-7445.AM2012-2696"},{"key":"key-10.4103\/1008-682X.129133-103","first-page":"Abstract 2854","volume-title":"The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC): presented at: European Cancer Congress 2013; September 27-October 1, 2013, Amsterdam","author":"Efstathiou","year":"2013","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/1008-682X.129133-104","first-page":"R183","volume-title":"Alternatively spliced androgen receptor variants","author":"Dehm","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"key-10.4103\/1008-682X.129133-105","first-page":"535","volume-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"key":"key-10.4103\/1008-682X.129133-106","first-page":"1309","volume-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"key-10.4103\/1008-682X.129133-107","unstructured":"Press Release: medivation and astellas announce the phase 3 PREVAIL trial of enzalutamide meets both co-primary endpoints of overall survival and radiographic progression-free survival in chemotherapy-naive patients with advanced prostate cancer."},{"key":"key-10.4103\/1008-682X.129133-108","first-page":"411","volume-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-109","first-page":"1502","volume-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-110","first-page":"1147","volume-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","author":"de","year":"2010","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.129133-111","first-page":"1756","volume-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.129133-112","first-page":"213","volume-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.129133-113","first-page":"5047","volume-title":"A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)","author":"Small","year":"2013","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-114","first-page":"1381","volume-title":"CD54 is a surrogate marker of antigen presenting cell activation","author":"Sheikh","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"key-10.4103\/1008-682X.129133-115","first-page":"717","volume-title":"Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy","author":"Hanania","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/1008-682X.129133-116","first-page":"5016","volume-title":"A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results","author":"Antonarakis","year":"2013","journal-title":"ASCO Meeting Abstr"},{"key":"key-10.4103\/1008-682X.129133-117","first-page":"4526","volume-title":"Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy","author":"Madan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-118","first-page":"555","volume-title":"New paradigms in microtubule-mediated endocrine signaling in prostate cancer","author":"Mistry","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"key-10.4103\/1008-682X.129133-119","doi-asserted-by":"crossref","unstructured":"Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2013 Jul 25. doi: 10.1016\/j.eururo.2013.07.022. [Epub ahead of print].","DOI":"10.1016\/j.eururo.2013.07.022"},{"key":"key-10.4103\/1008-682X.129133-120","first-page":"6019","volume-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","author":"Darshan","year":"2011","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-121","first-page":"7992","volume-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","author":"Zhu","year":"2010","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-122","first-page":"8386","volume-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","author":"Gan","year":"2009","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.129133-123","first-page":"3821","volume-title":"Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer","author":"van","year":"2013","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/1008-682X.129133-124","first-page":"2943","volume-title":"Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?","author":"Mezynski","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.129133-125","first-page":"1807","volume-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","author":"Loriot","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.129133-126","first-page":"1802","volume-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.129133-127","first-page":"78","volume-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","author":"Bianchini","year":"2014","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/1008-682X.129133-128","first-page":"30","volume-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.129133-129","first-page":"995","volume-title":"Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer","author":"Miyamoto","year":"2012","journal-title":"Cancer Discov"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:23:55Z","timestamp":1786649035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.129133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"alternative-id":["129133"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.129133","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}